TEVA-MEDROXYPROGESTERONE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
26-02-2015
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
MEDROXYPROGESTERONE ACETATE
Inapatikana kutoka:
TEVA CANADA LIMITED
ATC kanuni:
G03DA02
INN (Jina la Kimataifa):
MEDROXYPROGESTERONE
Kipimo:
10MG
Dawa fomu:
TABLET
Tungo:
MEDROXYPROGESTERONE ACETATE 10MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100/500/1000
Dawa ya aina:
Prescription
Eneo la matibabu:
PROGESTINS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0106339006; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2011-01-18
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
TEVA-MEDROXYPROGESTERONE
medroxyprogesterone acetate tablets USP
2.5 mg, 5 mg and 10 mg
PROGESTIN
Teva Canada Limited
Date of Revision:
30 Novopharm Court
May 12, 2014
Toronto, Ontario
M1B 2K9
Control No: 173232
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
..........................................................................................................
16
DOSAGE AND ADMINISTRATION
......................................................................................
18
OVERDOSAGE
........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL
TRIALS..................................................................................................................
26
DETAILED PHARMACOLOGY
.............................................................................................
28
TOXICOLOGY
..............
Soma hati kamili
